GlycoMimetics, Inc. operates as a clinical-stage pharmaceutical company, specializing in the research and development of groundbreaking glycomimetic therapies. Its core mission is to address critical unmet medical requirements arising from various diseases within the United States. A key focus of their pipeline is uproleselan, an E-selectin inhibitor.